公开(公告)号：US20250041277A1

公开(公告)日：2025-02-06

申请号：US18715085

申请日：2022-12-01

Applicant: PFIZER INC.

Inventor： Lars ANDERS ,  Jerry LI ,  Tun Tun LIN ,  Ping WEI ,  Jing YANG ,  Todd Lee VANARSDALE

IPC: A61K31/4155 ,  A61K31/4196 ,  A61K31/506 ,  A61K31/565 ,  A61P35/00

Abstract: This disclosure relates to combination therapies for use in treating cancer, comprising a CDK2 inhibitor of Formula (I) and a selective CDK4 inhibitor of Formula (II), each as further described herein, optionally in further combination with an additional anti-cancer agent.

公开(公告)号：US20230321042A1

公开(公告)日：2023-10-12

申请号：US18017071

申请日：2021-07-16

Applicant: PFIZER INC.

Inventor： Stephen George DANN ,  Nichol Lee Goodman MILLER ,  Todd Lee VANARSDALE

IPC: A61K31/415 ,  A61K31/565 ,  A61P35/00 ,  A61K31/4196 ,  A61K31/519

CPC classification number: A61K31/415 ,  A61K31/4196 ,  A61K31/519 ,  A61K31/565 ,  A61P35/00

Abstract: This invention relates to combination therapies for use in treating cancer, comprising a cyclin dependent kinase 2 (CDK2) inhibitor of Formula (I), as further described herein, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, optionally in further combination with an additional anti-cancer agent=.